Stockreport

Genelux Corporation Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

Genelux Corporation  (GNLX) 
PDF -- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec dem [Read more]